New Haven, Conn. – October 08, 2026 -- Biohaven Ltd. (NYSE: BHVN) has signed a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN member states.